Phosphodiesterase and immune dysfunction in atopic dermatitis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Atopic dermatitis and the other atopic conditions occur as a result of direct or indirect influences from cells of hematopoietic origin. Cellular immune abnormalities have been described, but appear to be secondary to cutaneous inflammation in atopic dermatitis. Pharmacophysiologic abnormalities are numerous and may relate to defective cyclic nucleotide metabolism in circulating and infiltrating leukocytes. A consistent leukocyte abnormality is elevated cyclic AMP-phosphodiesterase. This enzyme abnormality results in reduced intracellular cyclic AMP, creating a net permissive effect upon cell function. Phosphodiesterase inhibitors have been demonstrated to reduce abnormal histamine release and IgE production by cultured leukocytes. Studies of phosphodiesterase and associated defects in atopic leukocytes may lead to delineation of basic pathogenetic mechanisms as well as providing the potential for therapeutic targeting.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalJournal of Dermatological Science
Volume1
Issue number1
DOIs
StatePublished - 1990

Fingerprint

Phosphoric Diester Hydrolases
Atopic Dermatitis
Cyclic AMP
Leukocytes
Phosphodiesterase Inhibitors
Cyclic Nucleotides
Metabolism
Immunoglobulin E
Histamine
Defects
Histamine Release
Enzymes
Inflammation
Skin
Therapeutics

Keywords

  • Atopic dermatitis
  • Atopic leukocytes
  • Immune dysfunction
  • Pathogenic mechanisms
  • Phosphodiesterase
  • Therapeutic targeting

ASJC Scopus subject areas

  • Dermatology

Cite this

Phosphodiesterase and immune dysfunction in atopic dermatitis. / Hanifin, Jon.

In: Journal of Dermatological Science, Vol. 1, No. 1, 1990, p. 1-6.

Research output: Contribution to journalArticle

@article{c355fef2535b4116a65b42000064e8da,
title = "Phosphodiesterase and immune dysfunction in atopic dermatitis",
abstract = "Atopic dermatitis and the other atopic conditions occur as a result of direct or indirect influences from cells of hematopoietic origin. Cellular immune abnormalities have been described, but appear to be secondary to cutaneous inflammation in atopic dermatitis. Pharmacophysiologic abnormalities are numerous and may relate to defective cyclic nucleotide metabolism in circulating and infiltrating leukocytes. A consistent leukocyte abnormality is elevated cyclic AMP-phosphodiesterase. This enzyme abnormality results in reduced intracellular cyclic AMP, creating a net permissive effect upon cell function. Phosphodiesterase inhibitors have been demonstrated to reduce abnormal histamine release and IgE production by cultured leukocytes. Studies of phosphodiesterase and associated defects in atopic leukocytes may lead to delineation of basic pathogenetic mechanisms as well as providing the potential for therapeutic targeting.",
keywords = "Atopic dermatitis, Atopic leukocytes, Immune dysfunction, Pathogenic mechanisms, Phosphodiesterase, Therapeutic targeting",
author = "Jon Hanifin",
year = "1990",
doi = "10.1016/0923-1811(90)90003-V",
language = "English (US)",
volume = "1",
pages = "1--6",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Phosphodiesterase and immune dysfunction in atopic dermatitis

AU - Hanifin, Jon

PY - 1990

Y1 - 1990

N2 - Atopic dermatitis and the other atopic conditions occur as a result of direct or indirect influences from cells of hematopoietic origin. Cellular immune abnormalities have been described, but appear to be secondary to cutaneous inflammation in atopic dermatitis. Pharmacophysiologic abnormalities are numerous and may relate to defective cyclic nucleotide metabolism in circulating and infiltrating leukocytes. A consistent leukocyte abnormality is elevated cyclic AMP-phosphodiesterase. This enzyme abnormality results in reduced intracellular cyclic AMP, creating a net permissive effect upon cell function. Phosphodiesterase inhibitors have been demonstrated to reduce abnormal histamine release and IgE production by cultured leukocytes. Studies of phosphodiesterase and associated defects in atopic leukocytes may lead to delineation of basic pathogenetic mechanisms as well as providing the potential for therapeutic targeting.

AB - Atopic dermatitis and the other atopic conditions occur as a result of direct or indirect influences from cells of hematopoietic origin. Cellular immune abnormalities have been described, but appear to be secondary to cutaneous inflammation in atopic dermatitis. Pharmacophysiologic abnormalities are numerous and may relate to defective cyclic nucleotide metabolism in circulating and infiltrating leukocytes. A consistent leukocyte abnormality is elevated cyclic AMP-phosphodiesterase. This enzyme abnormality results in reduced intracellular cyclic AMP, creating a net permissive effect upon cell function. Phosphodiesterase inhibitors have been demonstrated to reduce abnormal histamine release and IgE production by cultured leukocytes. Studies of phosphodiesterase and associated defects in atopic leukocytes may lead to delineation of basic pathogenetic mechanisms as well as providing the potential for therapeutic targeting.

KW - Atopic dermatitis

KW - Atopic leukocytes

KW - Immune dysfunction

KW - Pathogenic mechanisms

KW - Phosphodiesterase

KW - Therapeutic targeting

UR - http://www.scopus.com/inward/record.url?scp=0025275833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025275833&partnerID=8YFLogxK

U2 - 10.1016/0923-1811(90)90003-V

DO - 10.1016/0923-1811(90)90003-V

M3 - Article

C2 - 1964082

AN - SCOPUS:0025275833

VL - 1

SP - 1

EP - 6

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 1

ER -